Assertio Therapeutics
在场
高管
查看带有其 15 名主要高管的组织结构图
Assertio Therapeutics 搜索最多的简介
- Heather Mason, Interim Chief Executive Officer and Director
- James Tyree, Independent Director
- Peter Staple, Chairman of the Board
高管在Assertio Therapeutics变化
- Sigurd Kirk已作为Director加入公司 (新闻发布的2024四月5号).
- Daniel Peisert, Chief Executive Officer and Director, 已经离开公司 (新闻发布的2024一月4号).
- Heather Mason 曾任 Director, 现升职为 Interim Chief Executive Officer and Director (新闻发布的2024一月4号).
创建提醒
跟踪 Assertio Therapeutics 的高管变动
药店
Assertio Therapeutics 拥有 1,867 家竞争者，其中包括 Pfizer (美国(美洲))、Sanofi (法国) 和 Johnson & Johnson (美国(美洲))。
Popular M&A news in 药店
- AstraZeneca has announced the acquisition of Fusion Pharma (公布2024三月23号).
- AstraZeneca has announced the acquisition of Amolyt Pharma (公布2024三月19号).
- Frontier Medicines 刚刚宣布为 80 筹款数百万美元。 (公布2024二月27号).
药店 行业的其他推荐联系人
消息
Assertio Therapeutics 的最新新闻稿
- Sig Kirk Joins Assertio Board of Directors
- Assertio to Present at LD Micro Invitational Conference in New York City
- Assertio Reports Fourth Quarter and Full Year 2023 Financial Results
- Assertio Holdings, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 11, 2024
- Assertio Holdings, Inc. - Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Assertio Holdings, Inc. - Assertio Holdings, Inc. Announces Leadership Transition
- Assertio Holdings, Inc. - Assertio Reports Third Quarter 2023 Financial Results
- Assertio Holdings, Inc. - Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors
- Assertio Holdings, Inc. - Assertio Holdings, Inc. to Release Third Quarter 2023 Financial Results on November 8, 2023
- Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- View more press releases Close
通过电子邮件
